

Who we work with

The European Medicines Agency (EMA) engages with a wide range of EU patient, consumer and healthcare professional (HCP) organisations all along the medicines lifecycle.

These stakeholder groups bring along their real-life perspective, experience, knowledge and expertise to regulatory decisions.

Collaboration supports transparency and trust in regulatory processes.

Highlights of 2017

- First Public Hearing held at EMA
- Framework for collaboration with academia — adopted
- Agency adopts Principles for Involvement of Young People in its activities
- Personalised Medicines workshop report
- Information session on antimicrobial resistance
- Outcome report on patients in benefit/risk discussions at CHMP meetings


Number of activities and type of representation

925 Number of activities involving patients, carers and consumers




■ Representing community ■ Representing own organisation ■ As individuals

445 Number of activities involving HCPs (in addition to those nominated by national agencies)



Patients and HCPs input into benefit-risk assessments*



■ Scientific Advice meetings* ■ Scientific Advisory Groups

*Only showing patient figures for Scientific Advice meetings



■ Committee consultations

Participation in workshops

138 Patients participated in workshops as speakers and chairs, and audience members

83 HCPs participated in workshops as speakers and chairs, and audience members

Other activities

- Ongoing engagement with general practitioners/family doctors
- EMA action plan related to EC recommendations on product information
- Training and resources for patients
- HCPWP/PCWP joint work plans for 2018-2019

Training and resources

